Carmen Calfa
Hematology & Oncology · Hollywood, FLNPI 1114138534
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,022 of the $1,229 with a category attached, or 83.2%. It is spread thinly across 15 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $407, 5.3 times the $77 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 54 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$207
- Daiichi Sankyo Inc.$162
- Merck$134
- Novartis$127
- Mentor Worldwide LLC$115
- Pfizer$98
- plus $386 from 9 others
Across 25 payments — averaging $8113.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$199K
- Pfizer$2K
- Novartis$1K
What the payments were for
- Food & beverage$1,02283%
- Education$20717%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 4 | $207 |
| Daiichi Sankyo Inc. | 8 | $162 |
| Merck | 8 | $134 |
| Novartis | 6 | $127 |
| Mentor Worldwide LLC | 1 | $115 |
| Pfizer | 5 | $98 |
| AstraZeneca | 2 | $94 |
| Stemline Therapeutics Inc. | 4 | $76 |
| Janssen Scientific Affairs, LLC | 2 | $43 |
| Caris MPI, Inc. | 2 | $41 |
| Gilead | 2 | $36 |
| Tersera Therapeutics LLC | 1 | $31 |
| Veracyte, Inc. | 7 | $31 |
| Amgen | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,229 in reported general payments places this provider in the 30th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 20 | $391 |
| Zolpidem Tartrate | 22 | $188 |
| Anastrozole | 13 | $185 |
| Tramadol Hcl | 22 | $166 |
| Temazepam | 14 | $163 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 12 | $105 |
| Alprazolam | 14 | $25 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Hollywood
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.